Benefits
Exercise performance: small trials, mixed results
The controlled trials disagree. In 22 endurance-trained male cyclists, 3 g/day of Cs-4 for 5 weeks changed nothing: VO2 peak, ventilatory threshold and time-trial time were all unaffected, and two smaller cyclist trials of cordyceps combined with rhodiola were null as well. On the other side, 2 g/day for 12 weeks improved 5 km time in 22 amateur marathoners without changing VO2 max, and in 20 healthy adults aged 50 to 75 about 1 g/day of Cs-4 for 12 weeks raised the metabolic threshold 10.5 percent and the ventilatory threshold 8.5 percent from baseline while the placebo group did not change, though VO2 max moved in neither group and the authors called it a pilot. The one positive high-intensity result came from a 4 g/day six-mushroom blend, not from cordyceps on its own. Every one of these trials is small and none has been replicated.
ATP and mitochondrial signalling: animal data only
Cordycepin and adenosine are structural analogues that interact with adenosine receptors and with AMPK, and rodent work reports higher ATP content in liver and muscle after dosing. No trial has measured fatigue, subjective energy or work capacity as an endpoint in people, so this is a laboratory mechanism and not a demonstrated effect on how energetic anyone feels.
Immune blood markers in healthy adults
Two randomized placebo-controlled trials measured immune markers in healthy adults. In 79 healthy Korean men, 1.5 g/day of Cordyceps militaris for 4 weeks raised natural killer cell activity, lymphocyte proliferation, IL-2 and interferon gamma more than placebo. In 79 healthy adults, 1.68 g/day of a Cordyceps mycelium extract for 8 weeks raised natural killer cell cytotoxic activity by about 39 percent from baseline relative to placebo. Both results are blood test readings: neither trial counted colds, infections or days off sick, so a higher NK number is not the same as falling ill less often.
Antioxidant enzyme markers: cells and invertebrates
Cordyceps polysaccharides raise superoxide dismutase and glutathione peroxidase activity and lower oxidative stress markers in cell and animal work, and lifespan is extended in invertebrate models such as fruit flies and nematodes. None of that has been shown to produce a measured antioxidant or longevity outcome in people taking cordyceps.
Mechanism of action
Adenosine receptor agonism
Cordycepin (3'-deoxyadenosine) acts as an adenosine analog, binding adenosine receptors that regulate cellular energy status, mitochondrial function, and blood vessel dilation during exercise. This route belongs mainly to Cordyceps militaris. The fermented Cordyceps sinensis mycelium (Cs-4) used in the older-adult exercise trial carries little cordycepin, so it cannot be the explanation for that trial's result.
AMPK pathway activation
Cordyceps polysaccharides activate AMPK, stimulating mitochondrial biogenesis, fatty acid oxidation, and glucose uptake in muscle cells.
Erythropoiesis support
Cordyceps has been proposed to raise red blood cell production and 2,3-DPG in erythrocytes, which would improve oxygen unloading to tissues. The human data are thin: a 16-week trial in 22 long-distance runners reported better maintained hemoglobin, hematocrit and ferritin than placebo, while no study has measured 2,3-DPG in people taking cordyceps, and the randomized cycling trials found no change in VO2 peak or ventilatory threshold.
Clinical trials
Double-blind, placebo-controlled pilot trial of Cs-4 (a cultured Cordyceps sinensis mycelium extract) at 333 mg three times daily, about 1 g/day, versus placebo in 20 healthy adults aged 50 to 75 over 12 weeks. Outcomes: VO2 max, metabolic (lactate) threshold and ventilatory threshold on a cycle ergometer. (Chen et al. 2010, J Altern Complement Med)
20 healthy older adults aged 50 to 75. 12-week intervention.
Within the Cs-4 group the metabolic threshold rose 10.5 percent (p < 0.02) and the ventilatory threshold rose 8.5 percent, with no such change in the placebo group. VO2 max did not change in either group. These are changes from baseline within each arm: the paper reports no direct between-group comparison, and the authors describe it as a pilot study. Cs-4 is a cultured mycelium strain of Cordyceps sinensis, not the wild fungus, which is one of the most expensive fungi in the world and is not what supplements contain.
Randomized, double-blind, placebo-controlled trial of 4 g/day (1.3 g three times daily) of a mushroom blend (PeakO2, Compound Solutions) versus a maltodextrin and hemp protein placebo in 28 healthy young adults for 1 week, after which only 10 volunteers continued for a further 2 weeks. The blend contains Cordyceps militaris alongside reishi, king trumpet, shiitake, lion's mane and turkey tail, so no result here can be assigned to cordyceps by itself. Funded by Disruptive Nutrition. Outcomes: VO2 max, ventilatory threshold, time to exhaustion, peak and average power. (Hirsch et al. 2017, J Diet Suppl)
28 healthy young adults (mean age about 23) in the 1-week phase; only 10 of them continued to 3 weeks.
After 1 week there was no significant time by treatment interaction for VO2 max (p = 0.364), ventilatory threshold (p = 0.514), time to exhaustion (p = 0.540), peak power (p = 0.134), average power (p = 0.398) or power drop (p = 0.823). The head to head comparison was null. The reported gains are within-group: a confidence interval analysis showed time to exhaustion rising in the blend group but not placebo at 1 week (about 28 seconds) and 3 weeks (about 70 seconds), and VO2 max rising in the blend group at 3 weeks (p = 0.042), among the roughly 10 people who continued that far. Industry funded, and the tested product is a six-mushroom blend, so the finding belongs to the blend and not to cordyceps alone. Cordyceps militaris is also a different species from the Cordyceps sinensis used in the older-adult trial, with a different cordycepin content.